Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1CNS 1

Conditions

Melanoma 15Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Brain Neoplasms 2Uveal Melanoma 1Patient Preference 1Melanoma, Cutaneous Malignant 1Lymphoma 1Locally Advanced Melanoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Opdualag × Clear all
NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Australian & New Zealand Children's Haematology/Oncology Group

Phase 1/2 Recruiting
90 enrolled
CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT05970497 2025-05-18

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Krystal Biotech, Inc.

Phase 1/2 Recruiting
240 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡